Is Dhanvantri Jeev. overvalued or undervalued?

As of 13 October 2025, the valuation grade for Dhanvantri Jeev. has moved from attractive to very attractive, indicating a significant improvement in its valuation outlook. The company is currently considered undervalued. Key ratios supporting this conclusion include a PE ratio of 11.98, an EV to EBITDA of 9.43, and a PEG ratio of 0.26, all of which suggest that the company is trading at a discount compared to its earnings growth potential.
In comparison to its peers, Dhanvantri Jeev. stands out with a much lower PE ratio than Max Healthcare, which has a PE of 92.33, and Apollo Hospitals, which has a PE of 70.2. The EV to EBITDA ratio of 9.43 also highlights its relative value against the industry backdrop, where peers like Fortis Health are valued at 49.19. Additionally, the company's stock has shown strong performance, with a year-to-date return of 30.62%, significantly outpacing the Sensex return of 5.36% during the same period, reinforcing its undervalued status.